Medpace Holdings, INC Form 4 insider transactions

Medpace Holdings, Inc. Director Cornelius P. McCarthy III has scheduled the exercise of stock options to acquire 1,972 shares of common stock at $54.99 per share, effective July 22, 2025, under a Rule 10b5-1 plan.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III exercised 4,500 stock options at $54.99 per share, increasing his direct beneficial ownership of common stock to 9,887 shares.

Medpace Holdings, Inc. Director Cornelius P. McCarthy III converted 50 restricted stock units into common stock on June 30, 2025, increasing his direct beneficial ownership of common stock.

Medpace Holdings, Inc. Director Robert O. Kraft converted 57 restricted stock units into common shares on June 30, 2025, as part of a pre-scheduled vesting.

Medpace Holdings, Inc. Director Brian T. Carley reported the acquisition of 62 shares of common stock through the conversion of restricted stock units, increasing his direct beneficial ownership to 26,157 shares.

Director Dani S. Zander acquired stock options in Medpace Holdings, Inc. on May 16, 2025.

Cornelius P. McCarthy III, a director of Medpace Holdings, Inc., acquired stock options exercisable for 1,224 shares of common stock.

Robert O. Kraft, a director of Medpace Holdings, Inc., acquired 1,224 stock options at a price of $305.66 on May 16, 2025, according to a Form 4 filing.

Director Femida H. Gwadry-Sridhar acquired stock options in Medpace Holdings, Inc. on May 16, 2025.

Director Fred B. Davenport Jr. of Medpace Holdings, Inc. reports the acquisition of stock options and changes in beneficial ownership of common stock.

Director Brian T. Carley of Medpace Holdings, Inc. reports the acquisition of stock options exercisable for 1,224 shares of common stock.

Director Fred B. Davenport Jr. of Medpace Holdings, Inc. exercised stock options and sold a portion of the acquired shares on April 24, 2025.

Cornelius P. McCarthy III, a director at Medpace Holdings, Inc., reports the acquisition of 50 shares of common stock through the exercise of restricted stock units on March 31, 2025.

Director Robert Kraft reports the vesting of restricted stock units in Medpace Holdings, Inc.

Director Brian T. Carley reports a transaction involving Medpace Holdings, Inc. common stock and restricted stock units.

CEO August J. Troendle reports exercising stock options and acquiring/disposing of Medpace Holdings (MEDP) common stock on March 7, 2025.

Jesse J. Geiger, President of Medpace Holdings, reports the acquisition of stock options.

Stephen P. Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reports acquisition of stock options.

Susan E. Burwig, Executive VP of Operations at Medpace Holdings, Inc., reports the acquisition of 11,017 shares through a stock option grant.

Medpace Holdings CFO Kevin M. Brady reports the acquisition of stock options and disposal of common stock.

Stephen Ewald, General Counsel & Corp. Secy. of Medpace Holdings, Inc., reports purchasing 2 shares of common stock at $326.11 on February 27, 2025, increasing his holdings to 13,343 shares.

Director Brian T. Carley exercised stock options and sold shares of Medpace Holdings, Inc. on February 24, 2025.

Director Cornelius P. McCarthy III of Medpace Holdings, Inc. reports the exercise of stock options and vesting of restricted stock units on December 31, 2024.

Director Robert Kraft reports the vesting and subsequent disposal of restricted stock units in Medpace Holdings, Inc.

Brian T. Carley, a director at Medpace Holdings, reported the vesting of restricted stock units on December 31, 2024.

Medpace Holdings President, Jesse J. Geiger, exercised stock options for 15,000 shares at a price of $32.05 per share.

Medpace Holdings director Cornelius P. McCarthy III acquired 198 restricted stock units, which vest in four equal installments throughout 2025.

Robert O. Kraft, a director at Medpace Holdings, acquired 227 restricted stock units on November 29, 2024.

Medpace Holdings director Brian T. Carley acquired 249 restricted stock units, each representing a contingent right to receive one share of MEDP common stock, on November 29, 2024.

Medpace Holdings Executive Vice President, Operations, Susan E. Burwig, exercised stock options for 7,500 shares at $32.05 per share on November 19, 2024.